Unravel Biosciences

Executive Summary

Unravel Biosciences is a privately held biotechnology company based in Cambridge, MA, founded in 2019. The company leverages artificial intelligence and systems biology to transform drug discovery by repurposing existing drugs. Its proprietary platform builds 'Living Molecular Twins'—patient-derived RNA data models of biological networks—to clinically derisk new therapeutic targets. By simulating disease networks, Unravel identifies drug candidates that reverse aberrant gene expression signatures, enabling rapid identification of effective treatments for complex disorders. The company's initial focus is on rare neurological diseases, particularly Rett syndrome, where it aims to bring safe, repurposed therapies to patients faster than traditional drug development. Unravel's approach addresses two critical challenges in drug development: the high failure rate of novel targets and the long timelines for rare disease therapies. By starting with approved drugs and using AI to match them to disease biology, the company reduces risk and accelerates clinical entry. While still in early stages, Unravel has the potential to disrupt the rare disease therapeutic landscape. Key near-term milestones include advancing its lead program toward the clinic, expanding partnerships, and securing additional funding to support platform validation and pipeline growth.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 1/2 clinical trial for lead repurposed drug in Rett syndrome40% success
• H1 2027Strategic partnership or licensing deal with a larger pharmaceutical company for platform access60% success
• Q3 2026Peer-reviewed publication of preclinical validation data for the Living Molecular Twin platform in a rare disease80% success